德琪醫藥希維奧®獲韓國醫保批准,亞太地區市場進一步拓展
德琪醫藥宣佈,韓國國民健康保險公團(NHIS)批准希維奧®(塞利尼索片)納入醫保,用於治療復發/難治性多發性骨髓瘤(R/R MM)成人患者。希維奧®將於2024年7月1日起正式納入韓國醫保報銷藥品目錄。希維奧®是首款獲NHIS批准納入醫保,用於治療R/R MM成人患者的XPO1抑制劑。這是繼中國大陸、澳大利亞和新加坡之後,公司在第四個亞太地區市場實現對於希維奧®的國家醫保覆蓋。公司預計希維奧®將在亞太地區的更多國家獲得醫保收錄。公司已在包含泰國、馬來西亞和印度尼西亞在內的多個東盟國家提交了希維奧®的新藥上市申請(NDA),這些申請預計將於2024年下半年獲得批准。希維奧®是全球首個全新機制的口服選擇性核輸出蛋白(XPO1)抑制劑,具有“全新機制、協同增效、快速起效、持久緩解”四大特點,已在全球40多個國家和地區獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.